

Subject Index

AAdhesion molecules, neuroendocrine tumors and, 51
Adrenal gland, glycine receptor and, 159
Adrenal medulla
 catecholamine transporter of, 185
 chromaffin granules of, 36
Adrenoceptor stimulation, tumor models and, 383
AIDS, intestinal immune system and, 80
Albumin, heparan sulfate proteoglycans and, 349
Alpha-interferon, carcinoid tumors and, 472
Amine production, BON cell line and, 395
Amine precursor uptake decarboxylase (APUD), 1
 α -Amino-3-hydroxy-5-methyl-isoxazole-propionic acid (AMPA) receptors, 169
Amylase gene transcription, 109
Antitumor action, mechanism of, 476
APUD, 1
AR42J cells, rat pancreatic, 407
ARF protein, 347
AtT-20 cells, 220

BBeta-COP, Golgi transport and, 345
Biochemical markers, time of first expression of, 57
BON cell line, 393
Botulinum toxin, targets of, 224
Bovine vesicular monoamine transporter, cloning of, 187
Breast tumor, human, somatostatin receptors and, 149
Bromodeoxyuridine, mastomys and, 368

C Ca^{2+} /calmodulin, NO/cGMP system and, 360

Ca^{2+} channels
 electrically active neuroendocrine cells and, 338
 kinetics of G-protein-dependent modulations of, 307
Calcium imaging, 164
Calcium permeability, 168
Carbonylcyanide m. chlorophenylhydrazone (CCCP), 187
Carcinoid, midgut, 451
Carcinoid heart disease
 echocardiography for, 437
 surgical management of, 468
Carcinoid tumors, 380
Carcinoids, 418
Catecholamine release, chromogranin A and, 39
Catecholamine transporter, 185
Cell division and differentiation, 56, 59
Cell hyperplasia, ECL, 26
Chemotherapeutic agents, effect of, on BON tumor growth, 399
Chemotherapy, carcinoid patients and, 469
Chimera, N519H, 215
Cholecystokinin, pancreatic RIN C2 cells producing, 335
Chromaffin cells, 189
 extracellular role on, 38
Chromaffin granules, G-protein heterotrimers and, 300
Chromogranin A, neuroendocrine expression of, 36
Chronic atrophic gastritis, 27
Cisplatin, metastatic neuroendocrine tumor and, 469
Clathrin-coated pits, insulin-receptor internalization and, 273
Cloning, 176
Clostridial neurotoxins, 286
 molecular mechanisms of, 245
Clostridium botulinum, 245
Clostridium tetani, 245
Co-culture experiments, 348

- Coated-vesicle V-ATPase, 204
Collagens, ECM and, 89
Consensus sequences for steroid hormone-responsive elements, 105
Constitutive exocytosis, 9
Cross-linking assay, 148
Coproheptadine, 468
mastomys ECL cells and, 373
Cytokeratin, BON tumor and, 398
Cytoplasmic machinery, secretory granules and, 236
Cytoreductive hepatic surgery, 467

Desensitization, receptor, 165
Dexamethasone, substance-P receptor gene expression and, 413
Diacylglycerol (DAG), PKC and, 313
Diagnosis and treatment, new molecular aspects for, 515
Diffuse endocrine system, 1
Dihydrotetrabenazine (TBZOH), 186
Docking hypothesis, 280
Dosimetry, carcinoid tumors and, 493
Doxorubicin, neuroendocrine gut and pancreatic tumors and, 449, 472
Duodenum, neuroendocrine tumors of, 425

Echocardiography
carcinoid heart disease and, 437
carcinoid syndrome and, 466
ECLoma, 27
Electrical activity, spontaneous, in various neuroendocrine cells, 337
Endocrine tissues, signaling pathways in, 331
Endosomes, 218
synaptic-like microvesicles and, 239
Endosonography, 425
Enterochromaffin-like (ECL) cell growth, 32
Enterochromaffin-like (ECL) cells, 24
Enteropathy, gluten-sensitive, 83
Enzymology, soluble guanlyl cyclase, 357
Epitheliomesenchymal interactions, pancreas and, 70
Estradiol, mastomys ECL cells and, 373

Etoposide, metastatic neuroendocrine tumor and, 469
Exocytic fusion complex, putative, 252
Exocytosis, 223
 Ca^{2+} -triggered, 290
permeabilized neuroendocrine cells and, 298
Extracellular matrix, cellular proliferation and differentiation and, 87

Fibronectins, laminins vs., 90
 α -Fluoromethylhistidine, ECL cells and, 32
5-Fluorouracil, neuroendocrine gut and pancreatic tumors and, 449, 472
Forskolin, histamine secretion and, 375

G proteins, 223
heterotrimeric, 298
secretory defects in neuroendocrine tumor cells and, 519
slow changes of the level of, 309
GABA-secretion, neuroendocrine cells, 407, 524
GABA_A-receptors, neuroendocrine cells, 524
Gastric mucosa, somatostatin receptors in, 124
Gastric neoplasia, rodent species mastomys and, 365
Gastrin/somatostatin binding, BON cell line and, 398
Gastrin-stimulated histamine release, 373
Gastrinoma, endosonographic image of, 432
Gastrinomas, 419
Gastritis, ECLoma and, 27
Gastroenteropancreatic (GEP) tumors, 127
diagnosis and treatment of, 515
somatostatin-receptor scintigraphy in, 416
Gene, α -amylase 2, 107
Genetics of multiple endocrine neoplasia type 1, 453
Germinal zone, cell proliferation in, 56
Glucagonoma, octreotide and, 499

- Glucagonoma syndrome, 452
Glucocorticoids, substance P receptor gene expression modulated by, 410
Glycine receptor, inhibitory, 155
Golgi complex, Rab6 associated with, 340
Growth factors, expression of, 46
GTP γ S, 354
Gut-associated lymphoid tissue (GALT), somatostatin receptors in, 125
- H** H^+ /monoamine antiport, 185
 H^+ -electrochemical gradient, 185
Heart valve surgery, 444
Heparan sulfate proteoglycans, delivery of, from *trans*-Golgi network, 347
Hepatectomy, total, 512
Hepatic arterial devascularization, carcinoid patients and, 469
Hepatic arteries
 microembolization of, 480
 occlusion of, 480
 surgical ligation of, 480
Hepatocytes, trans-Golgi network and, 345
Heterotrimeric G proteins, voltage-dependent calcium channels and, 306
Histamine, ECL cells and, 24
HIV infection, intestinal immune system and, 80
H,K-ATPase, 213
Hormonal repression, 108
Hormone storage vesicle proteins, 36
Hormones, neuropeptides, and neurotransmitters, synthesis of, 516
Human carcinoid disease, 380
Human somatostatin receptor subtypes, 129
- I**Inflammatory bowel disease
 etiology of, 78
 somatostatin receptors in, 132
Insulin transcriptional expression, pancreas and, 69
Insulin-receptor internalization, 266
- Insulinoma, 220, 419
 endosonographic image of, 431
Interferon, metastatic carcinoid tumor and, 468
Intracellular signaling, PKC in, 313
Intracellular targeting, V-ATPases and, 206
Intraocular transplantation, 380
Ion pumps, 212
Ion-gated receptors, 519
Isoenzymes, PKC and, 313
- K**Ketanserin, 186
Ki-ras oncogenes, 118
- L** L_1 molecule, 11
Lamina propria lymphocytes, intestinal, 75
Laminins, ECM and, 89
Large dense core vesicles (LDCV), 517
 exocytosis and, 298
5-Lipoxygenase, 328
Liver, neuroendocrine tumors metastatic to, 479
Liver transplantation, 507
 survival after, 511
LLC-PK₁ cells, 214
Low-density lipoprotein receptor, 326-327
Loxtidine, gastric mucosa of mastomys and, 372
Lymph node metastases, 451
Lymphomas, gastrointestinal, 131
- M**Malignant carcinoid syndrome, 464
Markers, serum and plasma, 52
Mastomys, enterochromaffin-like cell pathobiology of, 365
Mastomys natalensis, 393
Mechanisms of transcriptional repression, 110
Medullary thyroid carcinoma, 453
Membrane proteins, secretory granules and, 233
Membrane trafficking components, regulated and constitutive, 257
Meta-iodobenzylguanidine (MIBG), 185, 489

- Metastatic carcinoid disease, liver transplantation and, 508
Metastatic carcinoid tumors, 464
Microembolizations, sequential, 481
Microvilli, insulin-receptor internalization and, 268
Monoamine transporter cloning of, 197
regulation of, 199
structural properties of, 198-199
Mucosal immune system, intestinal, 75
Multidrug resistance, transporters and, 180
Multiple endocrine neoplasia type 1, genetics of, 453
Multiple endocrine neoplasia type 1 gene, 458
Mutant mice, 158
- N**_{a,K}-ATPase, 213
NEM-sensitive factor (NSF), 258
Neural cell adhesion molecule (NCAM), 10
Neural crest, 4
Neurexin, 294
Neuroendocrine cell system, definition of, 18
Neuroendocrine expression of chromogranin A, 36
Neuroendocrine markers, general, 19
Neuroendocrine tumors classification of, 20
diagnosis and treatment of, 515
endosonography of, 425
growth factors in, 50
Neuroepithelial cells, clonal cultures of, 63
Neuron differentiation signals, 65
Neuronal network, 163
Neurotransmitter receptor, 155
Neurotransmitters, 245
neuropeptides and, ontogeny of, 58
synthesis of hormones, neuropeptides, and, 516
Nitric oxide synthases, 357
Non-*N*-methyl-D-aspartate receptor, glutamatergic neurotransmission and, 163
Noncollagenous glycoproteins, ECM and, 89
- Noradrenaline transporter cloning and structure of, 197
function and pharmacology of, 193
ion dependence of, 195
pharmacological and clinical aspects of, 194
purification of, 196
substrates and inhibitors of, 194
Nuclear receptors, structure of, 104
Nucleocapsid protein, stimulation of ribozyme activity by, 118
Nucleocapsid protein NCp7 of HIV-1, 119
Nycomed gradient centrifugation, 369
- O**ctreotide, 447
mastomys ECL cells and, 373
radiotherapy with, 496
Oncology, SRIF receptors and SRIF analogues in, 139
- P**ancreas, neuroendocrine tumors of, 425
Pancreas carcinoma, model of development of, 116
Pancreatic organogenesis, 68
Pancreatic tumors, 115
Pancreatic-resective procedure, 513
Paraneurons, 5
Parietal cell, 213
Patch clamp technique, electrophysiological experiments and, 336
Peptide hormone, 2
Peptide production, BON cell line and, 395
Peptide receptors, mapping of, 497
Permeabilization techniques, cell membrane, 279
Permeabilized neuroendocrine cells, exocytosis in, 298
Pharmacology, SRIF-receptor subtypes and, 139
Pheochromocytoma, human, 187
Phospholipases, eicosanoid formation and, 325
Pleural metastasis, 449
Polymerase chain reaction, 164
Polymorphic loci, MEN1 locus at 11q13 and, 461

Positron-emission tomography, 446
Post-trans-Golgi network vesicles, 347
Potassium-stimulated [³H]GABA release from AR42J cells, 412
Primary hyperparathyroidism, 454
Prostaglandin (PG) H synthase, 328
Prostaglandin (PG) receptor, 331
Protein kinase C, in intracellular signaling, 313
Proteoglycans, ECM and, 92
Pulmonary valve, 439

Rab6, intracellular localization of, 340
Radiological technique, positron-emission tomography as, 446
Radiotherapy
gastroenteropancreatic tumors and, 488
octreotide, 496
Rat pancreatic AR42J cells, 407
Reaction mechanisms, No biosynthesis and, 358
Receptor-mediated endocytosis
internalization process and, 266
vacuolar acidification and, 203
Recycling vesicles, 240
Regulated compartments, 220
Regulated exocytosis, 3
Regulation of expression (trans-synaptic induction), 189
Reserpine, 186
Retrovirus-based vectors, 61
Ribozyme, Ki-ras, 117
Right atrium and ventricle, 439
RNA binding protein, stimulation of
Ki-ras ribozyme activity by, 115

Scintigraphy, octreotide and, 503
Seclp homologues, 286
Second-messenger coupling, SRIF-receptor subtypes and, 139
Secretion, strategies interfering with, 524
Secretogranin family, 37
Secretory granules, 37
biogenesis of, 233
BON tumor cell line and, 398
molecular aspects of, 223

Secretory mechanisms, primary cell cultures and, 387
Secretory pathway, neurons and, 516
Signal transduction cascade, 114
Small dense core vesicles (SDCV), 241
Small GTP-binding proteins (SGBPs), Golgi transport and, 344
Small intestinal transplants, 382
Small synaptic vesicles (SSV), 517
exocytosis and, 298
SNARE complex, 294
SNARE hypothesis, 281
Soluble guanylyl cyclase, forms of, 359
Soluble NSF attachment proteins (SNAPs), NSF and, 258
Somatostatin
ECL cells and, 32
radiolabeled, 465
radiotherapy and, 496
voltage-dependent Ca²⁺ channels and, 339
Somatostatin (SST14), receptors for, in human breast tumors, 147
Somatostatin analogue therapy, malignant carcinoid syndrome and, 469
Somatostatin mRNA, 123
Somatostatin receptor mRNA, 129
Somatostatin receptor scintigraphy, 416
Somatostatin receptor subtypes, 148
Somatostatin receptors, human gastrointestinal tissues and, 122
Somatostatin release inhibiting factor (SRIF)-receptor cloning, 138
Somatostatin therapy, 134
Sorting in endocrine and epithelial cells, 212
Spasmodic mouse, 158
Spastic mouse, 158
Steroid-hormone receptor, structure of, 103
Stomach, neuroendocrine tumors of, 425
Streptozotocin, neuroendocrine gut and pancreatic tumors and, 449, 472
Strychnine, 155
Substance P stimulation, AR42J cells and, 407

- Substrate promiscuity, 177
Surgical management, carcinoid heart disease and, 466
SV40 immortalized hypothalamic cell lines, 60
Synaptic vesicle, neurotransmitter release and, 256
Synaptic vesicle V-ATPase, 207
Synaptic vesicles, 9
 biogenesis of, 239
 neurotransmitter and, 290
Synaptic-like microvesicle (SLMV), 233
Synaptobrevin, 224, 282
 tetanus toxin and botulinic neurotoxins and, 248
Synaptophysin, 224, 291
Synaptoporin, 227
Synaptosomal-associated protein (SNAP)-25, 224, 282
 neurotransmitter release and, 259
 tetanus toxin and botulinic neurotoxins and, 248
Synaptotagmin, 224, 291
 neurotransmitter release and, 258
Syntaxins, 282
 botulinic neurotoxins and, 251
 neurotransmitter release and, 259
- T**-cell differentiation, Crohn's disease and HIV infection and, 81
Tamoxifen, mastomys ECL cells and, 373
Tenascin, 91
Tetanus toxin, targets of, 224
Tetrabenazine (TBZ), 186
Therapeutic impact, neuroendocrine tumor disease and, 524
Trans-Golgi network (TGN)
 secretory granules and, 233
 delivery of heparan sulfate proteoglycan from, 345
- Transcriptional activation, hormone-responsive elements and, 106
Transdifferentiation, 12
Transfection, 119
Transmitter, inhibitory, 155
Transporter, functional, identification of, 176
Transporters and neurotransmission, 174
Tricuspid valve, 438
Tubulovesicular elements (TVE), 213
Tumor radio resistance, 488
- U**ndifferentiated embryonic pancreatic epithelium, 72
Upper abdominal exenteration, 510
- V**-ATPases, 203
Vacuolar acidification, 203
Vagus, ECL cells and, 32
VAPP14 protein, 347
Vascular occlusion therapy
 complications of, 484
 liver metastases and, 479
Vascular system, somatostatin receptors and, 133
Verner Morrison syndrome, 471
Vesicular monoamine transporters, "classical" pharmacology of, 175
Vesicle-associated membrane proteins (VAMPs), 224
 neurotransmitter release and, 259
Vesiculogenesis and vesicle maturation, 517
- Z**inc-dependent peptidases, 227
Zollinger-Ellison syndrome, 27

Index of Contributors

Ahlman, H., 380-392

Ahlström, H., 446-452

Ahnert-Hilger, G., 298-305, 407-415,
515-525

Ajani, J. A., 479-487

Arnold, R., xi-xii

Augustine, G., 290-297

Bakker, W. H., 496-506

Barthel, A., 344-356

Bartz, C., 113-121

Bauer, M., 87-102

Bauerfeind, R., 233-244

Beato, M., 103-112

Bechstein, W. O., 507-514

Becker, C.-M., 155-162

Beckh, S., 163-173

Beilecke, U., 325-334

Beimling, P., 113-121

Bennett, M. K., 256-265

Bergström, M., 446-452

Betz, H., 290-297

Bjurling, P., 446-452

Bommert, K., 290-297

Bönisch, H., 193-202

Breeman, W. A. P., 496-506

Bruns, C., 138-146

Brüss, M., 193-202

Burger, M. M., 279-289

Bychkov, R., 335-339

Caplan, M. J., 212-222

Carpentier, J.-L., 266-278

Carrasco, C. H., 479-487

Cuber, J. C., 335-339

Dahlström, A., 380-392

Dannull, J., 113-121

Darr, U. M., 365-379

de Jong, M., 496-506

de Jong, R. J. B., 416-424

DeBello, W., 290-297

Desnos, C., 185-192

Dieterich, W., 87-102

Dop, F. J., 416-424

Duggan, M., 290-297

Ehnis, T., 87-102

Eriksson, B., 446-452, 471-478

Eskeland, N. L., 36-45

Evers, B. M., 393-406

Faßhauer, D., 344-356

Feng, Y., 203-211

Forgac, M., 203-211

Gasnier, B., 185-192

Gill, B. M., 36-45

Gittes, G. K., 68-74

Gottardi, C. J., 212-222

Goud, B., 340-343

Gratzl, M., 223-232

Habenicht, A. J. R., 325-334

Haller, H., 313-324, 407-415

Heitz, P. U., 18-23

Henry, J.-P., 185-192

Herkert, M., 155-162

Hescheler, J., 306-312, 335-339

Hesse, H., 103-112

Heuss, C., 279-289

Hodel, A., 279-289

Horisberger, U., 122-137

Hosford, D., 147-154

Hoyer, D., 138-146

Huttner, W. B., 233-244

Ishizuka, J., 393-406

- J**ahn, R., 245–255
 Janßen-Timmen, U., 325–334
 Janson, E. T., 471–478
 John, M., 335–339
 Jung, G., 113–121
- K**ahn, R. A., 344–356
 Kaupmann, K., 138–146
 Kimmig, B. N., 488–495
 Kipper, N., 344–356
 Kling, C., 155–162
 Klöppel, G., 18–23
 Kölby, L., 380–392
 Kooij, P. P. M., 496–506
 Krejci, E., 185–192
 Krenning, E. P., 416–424, 496–506
 Kuhse, J., 155–162
 Kvols, L. K., xi–xii, 464–470, 515–525
 Kwekkeboom, D. J., 416–424, 496–506

- L**agercrantz, J., 453–463
 Laissue, J., 122–137
 Lamberts, S. W. J., 416–424, 496–506
 Landelius, J., 437–445
 Langley, K., 1–17
 Långstrom, B., 446–452
 Larsson, C., 453–463
 Laskar, O., 174–184
 Lawton, G. P., 365–379
 Liehr, M.-L., 425–436
 Lilja, A., 446–452
 Lindner, K. J., 446–452
 Lindschau, C., 313–324
 Lübbert, H., 138–146
 Luft, F. C., 313–324
 Lundin, L., 437–445

- M**agner, R., 203–211
 Mahata, M., 36–45
 Mahata, S. K., 36–45
 Martinez, O., 340–343
 Massoulié, J., 185–192
 Mayer, B., 357–364
 Misgeld, U., 163–173
 Modlin, I. M., 365–379

- Moelling, K., 113–121
 Mueller, G., 113–121
 Mühlhardt, C., 155–162
 Myers, M., 203–211

- N**euhaus, P., 507–514
 Nickel, W., 344–356
 Niemann, H., 245–255
 Nilsson, O., 380–392

- O**'Connor, D. T., 36–45
 O'Connor, V., 290–297
 Öberg, K., 46–55, 446–452, 471–478
 Oei, H. Y., 416–424, 496–506
 Ohashi, M., 233–244

- P**accaud, J.-P., 266–278
 Parmer, R. J., 36–45
 Postema, P. T. E., 496–506
 Prévost, G., 147–154

- R**aulf, F., 138–146
 Reijis, A. E. M., 496–506
 Reubi, J. C., 122–137, 416–424
 Reuss, C., 113–121
 Riecken, E.-O., xi–xii, 75–86, 335–339, 407–415, 425–436, 515–525
 Roa, M., 340–343
 Rodman, J., 203–211
 Rosewicz, S., 407–415
 Roush, D. L., 212–222
 Rozansky, D. J., 36–45

- S**aul, B., 155–162
 Schaefer, T., 279–289
 Schaer, J.-C., 122–137
 Scherman, D., 185–192
 Scherübl, H., 335–339
 Schieferdecker, H. L., 75–86
 Schneider, T., 75–86
 Schoeffter, P., 138–146
 Schuldiner, S., 174–184
 Schultz, G., 306–312
 Schuppan, D., 87–102

Shirvan, A., 174–184
Siebert, A., 290–297
Slater, E. P., 103–112
Slepnev, V., 340–343
Söling, H.-D., 344–356
Somasundaram, R., 87–102
Soroka, C. J., 365–379
Specht, E., 325–334
Steiner-Mordoch, S., 174–184
Stern-Bach, Y., 174–184
Stölzel, U., 425–436
Sundler, F., 24–35
Surovoy, A., 113–121
Swandulla, D., 163–173

Takiyyuddin, M. A., 36–45
Tang, K., 36–45
Tang, L. H., 365–379
Teh, B. T., 453–463
Thomas, F., 147–154
Thompson, J. C., 393–406
Tixier-Vidal, A., 56–67
Tomiç, I., 325–334
Townsend Jr., C. M., 393–406

Ullrich, R., 75–86

Videen, J. S., 36–45
Visser, T. J., 496–506

Wallace, S., 479–487
Wängberg, B., 380–392
Waser, B., 122–137
Weber, G., 453–463
Weckbecker, G., 138–146
Wiedenmann, B., xi–xii, 113–121,
 298–305, 335–339, 407–415, 425–
 436, 515–525
Wu, H., 36–45

Yang, C., 340–343
Yelin, R., 174–184
Yoon, K., 113–121

Zeilhofer, H. U., 163–173
Zeitz, M., 75–86
Zhang, J., 203–211
Zhang, X., 36–45
Zhu, Z.-h., 365–379
Ziegler, K., 425–436
Zimmer, T., 425–436